Company to Hold First Quarterly Call as a Public Company on September 3,
2015
Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company
with a late-stage pipeline of innovative extended-release (“XR”) product
candidates for the treatment of attention deficit hyperactivity disorder
(“ADHD”), today announced that it will report financial results for the
second quarter and first half of 2015 before the market opens on
Thursday, September 3, 2015. Management will host a conference call
beginning at 8:30 a.m. Eastern Time that day to review results and
provide a company update.
To access the call, dial 866-842-7969 (U.S.) or 704-908-0466 (outside of
the U.S.). The Conference ID is 19474416. A live webcast will be
available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
Please log in approximately 5-10 minutes prior to the scheduled start
time.
The archived webcast will be available on the company’s Investor
Relations page under Presentations.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on
developing, manufacturing and commercializing products utilizing its
proprietary modified-release drug delivery technology platform. The
Company is initially focusing on ADHD and has developed three branded
product candidates that are XR medications in patient-friendly orally
disintegrating tablets (“ODT”) or liquid suspension dosage forms. In
addition, Neos manufactures and markets its generic equivalent of the
branded product Tussionex®1, an XR liquid suspension of
hydrocodone and chlorpheniramine indicated for the relief of cough and
upper respiratory symptoms of a cold.
1 Tussionex® is a registered trademark of the UCB Group of
Companies
View source version on businesswire.com: http://www.businesswire.com/news/home/20150825005410/en/
Copyright Business Wire 2015